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Background: Exhaled nitric oxide (eNO) is an established, noninvasive biomarker of active
airway inflammation in (atopic) asthma. Treatment with anti-inflammatory therapy, such as
inhaled corticosteroids, effectively decreases eNO levels. The NIOX MINO (MINO) is a hand-
held, relatively inexpensive, electrochemical device that has been shown to yield comparable
eNO measurements to the NIOX stationary unit.
Aim: To compare measurements of MINO with another widely used and validated stationary
chemiluminescence analyzer, the Ecomedics (ECO).
Methods: We performed subsequent eNO measurements on ECO and MINO in 50 subjects (19
healthy volunteers, 18 healthy smokers and 13 non-smoking, atopic asthmatics, not on
controller therapy) on two visits 4e10 days apart. The mean of three acceptable measure-
ments by ECO and the first acceptable measurement with the MINO were used for analysis.
Results: Both devices yielded reproducible eNO values for all subjects on both visits, with an
overall CV of 22.7% (ECO) and 18.3% (MINO). A significant correlation was found between both
devices (rZ 0.97, p< 0.0001). Bland-Altman plots showed a high degree of agreement for the
entire study population (mean difference MINO vs ECOZ10%; 95% limit of agreement were
36% and þ28%) and in the three individual subgroups.
Conclusions: Exhaled NO values measured with the MINO are reproducible and in agreement
with the ECO. Our results add further evidence to the reliability of the MINO and warrant its
applicability in research and clinical practice.
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Asthma is a chronic inflammatory disease presenting with
variable symptoms and mostly reversible airway obstruction
within the lower airways. According to international guide-
lines, modern asthma management is aimed at the suppres-
sion of airway inflammation by avoidance of allergens and
anti-inflammatory, ‘controller’ therapy.1 For optimal guid-
ance of disease control, measuring biomarkers of airway
inflammation has become increasingly important.1 To this
aim, several non- and semi-invasive sampling techniques
have been developed and validated.2
Exhaled nitric oxide (NO) is an established biomarker of
airway inflammation that may serve to monitor the
response to (novel) controller therapy. In asthma, elevated
levels of eNO have been shown to correlate with disease
severity, showing increases prior and during an asthma
exacerbation and decreases following anti-inflammatory
treatment.2 In addition, using eNO measurements to guide
individual doses of inhaled corticosteroids resulted in
reduced airway hyperresponsiveness along with an overall
lower dose of inhaled corticosteroids without compromising
asthma control.3,4
Stationary chemiluminescence NO analyzers are vali-
dated devices for online measurement of NO levels in
exhaled air.5 However, their usage is largely hampered by
their bulkiness and high costs. More recently, MINO has
been marketed for portable, online eNO measurements.
This hand-held and relatively inexpensive device is simple
to use and yields reproducible measurements, even when
performed by children at home.6 In addition, a recent
economic evaluation revealed that the use of MINO in the
treatment of asthma offers cost savings compared to
asthma management based on standard guidelines, while
both methods result in comparable health benefits.7 These
properties warrant its potential applicability in both
primary health care setting and in clinical trials. However,
its reliability needs to be fully assessed.
So far, MINO has been compared with the NIOX
stationary unit but, to our knowledge, not with the other
validated and widely used chemiluminescence analyzer,
ECO.8e10 In this study we compared eNO measurements by
MINO with the previously validated ECO in healthy volun-
teers, healthy smokers and atopic asthmatics.
Methods
Subjects
The study population consisted of three subgroups: 19
healthy volunteers, 18 healthy smokers and 13 non-
smoking, atopic asthmatics (Table 1).
The healthy volunteers were non-smokers for at least 12
months with less than 5 pack years (1 pack yearZ 20 ciga-
rettes or equivalent smoked per day for 1 year). The
healthy smokers were current smokers (last cigarette was
smoked 1e2 h before the study procedures) with a smoking
history of at least 10 pack years. The asthmatic-subgroup
only used inhaled short-acting b2-agonists as needed and
had no controller medication for at least 1 month prior to
the study. All had intermittent to mild persistent asthmaand clinical stability was assessed by stable lung function
(FEV1 within 10% on both study visits), absence of symptoms
and stable, infrequent use of rescue medication in the last
3 months. Atopy was demonstrated by a positive skin prick
test for at least 1 of 10 airborn allergens. None of the
participants had a history of airway infection in the
previous 4 weeks prior and during the study. All subjects
gave written informed consent and the study was approved
by the Ethics Committee of Leiden University Medical
Centre.
Study design
Exhaled NO measurements were performed in all subjects
on ECO and MINO on 2 study visits, 4e10 days apart. All the
measurements were performed during the same time of the
day (2 h).
Exhaled NO measurements
All eNO measurements were performed according to
current guidelines.11 Briefly, subjects were sitting in
upright position and wearing a nose clip during the eNO
measurements with both devices. They inhaled NO-free
air through the device and subsequently exhaled at
50 ml/s for approximately 10 s. The mean of the first three
technically acceptable measurements within 10% per-
formed with the ECO (Ecomedics CLD88sp; Ecomedics,
Duernten, Switzerland) were implicated into analysis. For
measurements by the MINO (Aerocrine AB, Solna, Sweden),
the first technically acceptable measurement was used for
analysis.10
Spirometry
Following eNO measurements, spirometry (forced expira-
tory volume in 1 s (FEV1), forced vital capacity (FVC) and
peak expiratory flow (PEF)) was performed according to
standardized lung function techniques by a calibrated
spirometer connected to a personal computer (Vmax
Spectra Sensor Medics; Cardinal Health, Houten, The
Netherlands).12
Analysis
As eNO values were not normally distributed, data were log
transformed prior to analysis. Comparisons between
healthy volunteers and the other subgroups were made
using an unpaired t-test. The reproducibility of both
devices was assessed by the within subject variation
between visits and expressed as a coefficient of variation
(CVZ the standard deviation expressed as percentage of
the mean). In order to compare both devices, data were
plotted in a scattergraph and the Pearson correlation was
calculated on log-transformed data. Bland-Altman plots
were made with the difference (ECOMINO) of measure-
ments of both methods on the y-axis and the mean of the
two methods on the x-axis, along with an estimation of
the upper and lower limit of agreement, being 1.96 times
the standard deviation (SD). The presented Bland-Altman
plots incorporated all data and were constructed as if every
Table 1 Patients’ characteristics at baseline
Healthy volunteers Healthy smokers Atopic asthmatics p-Value
Total number 19 18 13
Female : Male 10:9 9:9 8:5
Age (years) 41 (30e53) 40 (32e52) 29 (21e54)
FEV1 (% predicted) 104.4 (87.5e119.5) 103.6 (82.1e121.1) 91.8 (61.0e122.0)
Exhaled NO Ecomedics (ppb) 18.0 (7.4e35.5) 11.1 (4.7e20.5) 60.8 (10.9e184.6) <0.01a
Exhaled NO NIOX MINO (ppb) 20.3 (8.0e39.0) 12.2 (5e23) 63.8 (13e172) <0.01a
All values are given as mean (range).
a Healthy volunteers compared to healthy smokers and compared to atopic asthmatics.
Figure 1 Pearson correlation between exhaled NO levels
measured with the Ecomedics (x-axis) and the NIOX MINO
(y-axis) analyzer.
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and second visit independently yielded similar results.
All calculations were performed using SAS for windows
V9.1.2 (SAS Institute, Inc., Cary, NC, USA).
Results
One subject from the healthy non-smokers’ group produced
eNO values <5 ppb on both occasions. Two subjects (one
healthy volunteer and one atopic asthmatic) failed to
perform acceptable eNO measurements on the ECO. These
measures were excluded from analysis. All other subjects
completed the study and performed technically acceptable
manoeuvres on both study visits. Overall, healthy smokers
had significantly lower and atopic asthmatics significantly
higher eNO values compared to healthy volunteers (Table
1). Exhaled NO values by MINO were slightly, but not signif-
icantly, higher than the ECO values in all three subgroups
(Table 1).
Both devices yielded reproducible eNO values for all
subjects on both visits, with an overall CV of 22.7% (ECO)
and 18.3% (MINO). The Pearson correlation analysis yielded
an r of 0.975 (p< 0.0001) between eNO values measured by
MINO and ECO (Fig. 1).
In addition, Bland-Altman plots demonstrate agreement
between both devices in the entire study population and the
three subgroups (Fig. 2) for both low and high values of eNO.
Discussion
In recent years, eNO has become widely accepted as
a biomarker of airway inflammation in asthma. The avail-
ability of simple and reliable eNO measurements is of major
importance in the diagnosis and monitoring of day-to-day
asthma. Hence, we compared the hand-held MINO to the
widely used stationary ECO analyzer in a study population
consisting of three subgroups: healthy volunteers, healthy
smokers and atopic asthmatics not on controller therapy.
Apart from a good reproducibility of eNO values on both
study visits, a significant correlation and a high degree of
agreement was observed between eNO measurements
yielded by both devices. Subgroup analysis revealed a supe-
rior agreement in the high eNO ranges (atopic asthmatics)
compared to the low eNO ranges (healthy smokers).
However, with respect to the latter the group sizes were
too small to draw definitive conclusions. Our results are in
agreement with previous data comparing the MINO to the
stationary NIOX unit and extend the findings to anotherwidely used and validated chemiluminescence analyzer,
(Ecomedics).8e10
Exhaled NO values are not normally distributed and
require log-transformation prior to analysis.10 Therefore, in
the current paper the upper and lower limits of agreement
are presented in percentages difference which may not be
suitable for clinical interpretation. However, if we use the
mean value of eNO for the entire study population
(26.4 ppb for the ECO) and back-translate to an arithmetic
scale the upper and lower limit of agreement are þ7.4 ppb
and 9.5 ppb, respectively. In our study, both devices
yielded comparable eNO measurements in individual
subjects, while MINO systematically produced slightly
higher values. Although similar with other studies
comparing MINO with the NIOX stationary unit, this may
impact clinical interpretation if patients are assessed on
both devices alternately.3,4,10,13 Hence, the cut-off eNO
values should be adjusted for MINO. In a previously con-
ducted study comparing chemiluminescence analyzers,
the ECO produced overall lower eNO values than the other
stationary analyzers.14,15 In conclusion, it is clear that eNO
analyzers yield comparable, but not interchangeable eNO
values. This implicates that, ideally, in an individual
Figure 2 Bland-Altman plot of exhaled NO measurements using the Ecomedics vs NIOX MINO for the entire study population (a),
healthy volunteers (b), healthy smokers (c) and atopic asthmatics (d).
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same analyzer.
A potential issue may be the difference in lower
detection limits between the ECO (0.1 ppb) and the MINO
(5 ppb). Indeed, in this study one subject (smoker) had
to be excluded from analysis because his eNO values on
the ECO were under the detection limit of the MINO.
From a clinical perspective, this may not have conse-
quences since very low eNO values are not clinically rele-
vant in asthma. However, should the device need to be
employed in the lower detection range, this issue will
have to be resolved. This may explain the larger variance
between both devices in the smoker group, although the
subject numbers were too small to show a significant
difference in variances in the lower detection ranges
between study groups. Other studies comparing the MINO
device with chemiluminescence analyzers did not find
any difference between the lower and higher eNO
values.8,10
In conclusion, eNO values measured with MINO are
reproducible and generally in agreement with the ECO. Its
simplicity, relatively low costs and small size make the
MINO device more suitable than the stationary chemilumi-
nescence analyzers for primary healthcare and large
clinical trials. Conversely, it cannot be used in research
settings requiring more sophisticated measurements
including nasal NO, very high or low eNO values or
samplings at different flow rates. Our results add further
evidence to the reliability of MINO and warrant its applica-
bility in clinical practice and research.Conflict of interest
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